Recursion Pharmaceuticals – A company that uses AI to discover new drugs and to repurpose existing drugs for rare diseases.

Revolutionizing Drug Discovery: The Role of AI in Recursion Pharmaceuticals

Recursion Pharmaceuticals is a biotechnology company that is revolutionizing drug discovery by using artificial intelligence (AI) to identify new drugs and repurpose existing ones for rare diseases. The company was founded in 2013 by Chris Gibson, Dean Li, and Blake Borgeson, who were inspired by the potential of AI to transform the drug discovery process.

Recursion’s approach to drug discovery is based on the use of machine learning algorithms to analyze large datasets of biological information. The company has developed a proprietary platform called the Recursion Operating System (ROS), which uses AI to generate high-resolution images of cells and tissues. These images are then analyzed using machine learning algorithms to identify potential drug targets and to screen existing drugs for their effectiveness against specific diseases.

One of the key advantages of Recursion’s approach is its ability to identify new drug targets that would be difficult or impossible to discover using traditional methods. By analyzing large datasets of biological information, the company can identify patterns and relationships that would be difficult for human researchers to detect. This has led to the discovery of several new drug targets for rare diseases, including cerebral cavernous malformation and neurofibromatosis type 2.

In addition to identifying new drug targets, Recursion is also using AI to repurpose existing drugs for rare diseases. This approach involves screening large libraries of existing drugs to identify those that have the potential to treat specific diseases. By repurposing existing drugs, Recursion can accelerate the drug discovery process and bring new treatments to patients more quickly.

One example of Recursion’s success in repurposing existing drugs is its work on the rare genetic disorder Niemann-Pick type C (NPC). NPC is a devastating disease that affects the body’s ability to metabolize cholesterol and other lipids. There is currently no cure for NPC, and existing treatments are limited in their effectiveness.

Using its AI platform, Recursion identified a drug called hydroxypropyl-beta-cyclodextrin (HPβCD) as a potential treatment for NPC. HPβCD is a compound that is commonly used in the food and pharmaceutical industries, but had not previously been considered as a treatment for NPC. Recursion conducted preclinical studies of HPβCD in NPC mouse models, and found that the drug was able to significantly improve the animals’ survival and neurological function.

Based on these promising results, Recursion is now working to develop HPβCD as a treatment for NPC. The company has received funding from the National Institutes of Health and the NPC community to support its research, and is currently conducting clinical trials of the drug in humans.

Recursion’s success in using AI to discover new drugs and repurpose existing ones has attracted the attention of investors and pharmaceutical companies. The company has raised over $500 million in funding to date, and has formed partnerships with several major pharmaceutical companies, including Bayer and Takeda.

Looking to the future, Recursion is continuing to expand its platform and explore new applications of AI in drug discovery. The company is also committed to making its technology accessible to researchers and organizations around the world, with the goal of accelerating the development of new treatments for rare diseases.

In conclusion, Recursion Pharmaceuticals is a biotechnology company that is using AI to revolutionize drug discovery. By identifying new drug targets and repurposing existing drugs for rare diseases, the company is bringing new hope to patients and transforming the way that drugs are developed. With its innovative approach and commitment to collaboration, Recursion is poised to make a significant impact on the field of biotechnology in the years to come.